broggini massimo
机构: Istituto Mario Negri
每年引用次数
引用次数
引用: 12,180
H-指数: 63
I10-指数 : 195
出版物: 401
Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2
Giulio Rastelli , Andrew Anighoro , Martina Chripkova , Laura Carrassa
Cell Cycle 13 ( 14) 2296 -2305
29
2014
Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.
Giovanna Damia , Massimo Broggini
Cell Cycle 3 ( 1) 46 -50
40
2004
∆Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299
Elisa Caiola , Eleonora Marrazzo , Simona Alesci , Massimo Broggini
Tumor Biology 37 ( 2) 2015 -2021
2016
Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact.
Chiara Foroni , Massimo Broggini , Daniele Generali , Giovanna Damia
Cancer Treatment Reviews 38 ( 6) 689 -697
334
2012
Revisiting ovarian cancer preclinical models: Implications for a better management of the disease
Francesca Ricci , Massimo Broggini , Giovanna Damia
Cancer Treatment Reviews 39 ( 6) 561 -568
25
2013
Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs
Faina Vikhanskaya , Mobin M Siddique , Ming Kei Lee , Massimo Broggini
Clinical Cancer Research 11 ( 12) 4348 -4356
48
2005
PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth
Federica Polato , Annamaria Codegoni , Robert Fruscio , Patrizia Perego
Clinical Cancer Research 11 ( 19) 6835 -6839
219
2005
Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells
David Drutovic , Martina Chripkova , Martina Pilatova , Peter Kruzliak
Tumor Biology 35 ( 10) 9967 -9975
28
2014
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation.
Elisa Caiola , Marika Colombo , Giovanna Sestito , Monica Lupi
Cells 9 ( 8) 1766
1
2020
Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
Alice Iezzi , Elisa Caiola , Arianna Scagliotti , Massimo Broggini
BMC Cancer 18 ( 1) 1028
4
2018
Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients.
Faina Vikhanskaya , Massimo Broggini
International Review of Cytology-a Survey of Cell Biology 219 157 -198
8
2002
Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
Roberta Affatato , Paolo Mendogni , Alessandro Del Gobbo , Stefano Ferrero
Cancers 12 ( 12) 1 -13
1
2020
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.
Marika Colombo , Mirko Marabese , Giulia Vargiu , Massimo Broggini
Frontiers in Oncology 10 532292 -532292
2020
Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil
Monica Ganzinelli , Laura Carrassa , Francesca Crippa , Michele Tavecchio
Clinical Cancer Research 14 ( 16) 5131 -5141
38
2008
Analysis of Gene Expression in Early-Stage Ovarian Cancer
Sergio Marchini , Pietro Mariani , Giovanna Chiorino , Eleonora Marrazzo
Clinical Cancer Research 14 ( 23) 7850 -7860
34
2008
Influence of tumor on adriamycin concentration in blood cells.
Massimo Broggini , Tina Colombo , Silvio Garattini , Maria Grazia Donelli
Cancer Chemotherapy and Pharmacology 4 ( 3) 209 -212
12
1980
Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.
Tina Colombo , Massimo Broggini , Laura Torti , Eugenio Erba
Cancer Chemotherapy and Pharmacology 7 ( 2) 127 -131
26
1982
In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma
Massimo Broggini , Eugenio Erba , Luciano Morasca , Carmel Horgan
Cancer Chemotherapy and Pharmacology 16 ( 2) 125 -128
3
1986
Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX.
Alice Iezzi , Elisa Caiola , Massimo Broggini
Translational Oncology 9 ( 5) 458 -465
7
2016
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Rosaria Chilà , Terence Hall , Giovanni Abbadessa , Massimo Broggini
Translational Oncology 10 ( 2) 153 -157
6
2017